Cerebellar Ataxia
Conditions
Interventions
Intervention group:Electrode placement: Based on individualized finite element head models derived from brain imaging data, the distribution of the temporal interference (TI) electric field in the cer
Stimulation difference frequency: 50 Hz
Stimulation duration: 60 minutes per continuous session
Total treatment duration: 1 week of consecutive treatment.
Sponsors
Department of Neurology, Xuanwu Hospital
Eligibility
Sex/Gender
All
Age
45 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Disease Diagnosis (meet any one of the following criteria): Multiple System Atrophy Cerebellar Type (MSA-C): Diagnosis meets the criteria outlined in the Movement Disorders 2020 edition. Hereditary Cerebellar Ataxia: Confirmed by genetic testing (e.g., SCA1-3, FRDA, etc.). Immune-Mediated Cerebellar Ataxia: Positive for specific antibodies in serum/cerebrospinal fluid. (2) Absence of other neurodegenerative diseases; (3) Aged 45–75 years, both male and female; (4) Willing to participate in the study and having provided signed informed consent; (5) Ability to fully cooperate with the treatment and complete the 2-month follow-up.
Exclusion criteria
Exclusion criteria: (1) Individuals with severe internal medical diseases, psychiatric disorders, or those lacking legal capacity or with limited legal capacity; (2) Those with significant abnormalities in relevant laboratory tests or examinations (e.g., abnormal blood biochemical tests or electrocardiogram findings); (3) Individuals with intracranial metal foreign bodies, cardiac pacemakers, cardiac stents, or cochlear implants; (4) Patients with intracranial infections, acute-phase cerebral hemorrhage, or significantly increased intracranial pressure; (5) Those with severe hearing or visual impairment that prevents cooperation during examinations; (6) Presence of internal devices or objects such as pacemakers, aneurysm clips, artificial heart valves, ear implants, or metal fragments; (7) Other contraindications for MRI scanning, including foreign bodies in the eyes, skin, or body.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dynamic Gait Analysis; | — |
Secondary
| Measure | Time frame |
|---|---|
| Ataxia Scale;BBS; | — |
Countries
China
Contacts
Public ContactLin Hua
Xuanwu Hospital, Capital Medical University
Outcome results
None listed